Log In
Print this Print this

Antineoplastons (ANP) therapy

  Manage Alerts
Collapse Summary General Information
Company Burzynski Research Institute Inc.
DescriptionCombination of the synthetic amino acid derivatives Atengenal (antineoplaston A10) and Astugenal (antineoplaston AS2-1)
Molecular Target
Mechanism of Action 
Therapeutic Modality 
Latest Stage of DevelopmentPhase II
Standard IndicationBrain cancer
Indication DetailsTreat advanced non-operable brainstem glioma (BSG); Treat anaplastic astrocytoma; Treat diffuse, intrinsic brainstem glioma in pediatric patients; Treat glioma; Treat newly diagnosed anaplastic astrocytoma; Treat optic pathway glioma (OPG) in pediatric patients
Regulatory Designation

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today